Kymera Therapeutics, Inc. (KYMR) is a pioneering, research-focused biotechnology company committed to discovering, developing, and commercializing groundbreaking therapies categorized under targeted protein degradation (TPD). This novel therapeutic approach has the potential to tackle a vast range of diseases, including immuno-inflammatory disorders and cancers, which are beyond the reach of traditional treatments.
Founded in 2016 and based in Cambridge, Massachusetts, Kymera stands at the forefront of harnessing the body's natural protein degradation system, also known as the ubiquitin-proteasome system, to revolutionize the treatment of previously non-druggable and underserved conditions. The firm’s innovative pipeline leverages its proprietary Pegasus™ drug discovery platform, which represents a paradigm shift in the realm of drug discovery and development.
The Pegasus™ platform integrated with Kymera’s deep understanding of the mechanistic complexity of protein degradation aids in creating tailored therapies that can degrade disease-causing proteins. This selective degradation is unlike conventional methods which only inhibit the proteins.
The management team of Kymera, with their unprecedented experience in drug discovery, development, and commercialization, guide the company towards achieving its mission. These experts originate from diverse backgrounds such as genetics, immunology, and oncology, adding multifaceted benefits to the firm's inventive endeavours.
Kymera’s groundbreaking work has attracted significant interest from investors and the biotech industry as a whole, with the company's initial public offering (IPO) in August 2020 raising around $174 million. With this strong financial backing, the company boosts its potential to expedite the development of its lead programs into critical trials and bring novel therapies to patients in need.
The business model of Kymera Therapeutics also incorporates strategic collaborations with major pharmaceutical companies, such as Sanofi. These alliances further enable an expansion of Kymera's reach to global patient populations, while enhancing the company's economic efficiencies and broadening its overall discovery capability.
Kymera is not only creating a new category of protein degraders, but it is also redefining boundaries of drug discovery and development. By reaching beyond traditional treatment methods to address challenging diseases, the company embodies the true spirit of innovation in the biotech industry. Consequently, Kymera Therapeutics, Inc. continues to be a leader in the thrilling space of targeted protein degradation, ultimately progressing towards a healthier future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
BofA Securities has raised its price target for Kymera Therapeutics (KYMR) to $144 from $123. The company currently holds an average rating of "buy" and a mean price target of $137.73 among analysts.
California State Teachers Retirement System significantly increased its holdings in Kymera Therapeutics, Inc. during the second quarter, now owning 7.51% of the company. Despite the company remaining unprofitable, it reported strong revenue growth and beat analyst expectations for its adjusted loss per share. Wall Street analysts maintain a "Moderate Buy" rating for Kymera Therapeutics, although company insiders have sold a substantial amount of stock.
Squarepoint Ops LLC significantly increased its stake in Kymera Therapeutics (NASDAQ:KYMR) by 657% in the second quarter. This move aligns with positive sentiment from other institutional investors and Wall Street analysts, who largely rate the stock as a "Buy" with an average target price higher than its current trading price. Despite strong institutional buying and better-than-expected quarterly results, the article notes substantial insider selling totaling $386.9 million over the past 90 days.
Legal & General Group Plc recently acquired 36,237 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) worth approximately $4.16 million during the second quarter. This move aligns with other institutional investors, including BlackRock and Merck, establishing new positions in the company. Despite insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $128.70, following strong quarterly results where Kymera exceeded revenue and earnings per share expectations.
Kymera Therapeutics insider Brian Adams sold 6,371 shares of the company's stock for approximately $744,324 to cover tax withholding obligations. This sale reduced his holdings by 11.25% to 50,254 shares. The company's stock rose 0.1% to $117.39, with a market cap of $9.76 billion, and beat earnings and revenue expectations in its last quarter.
Atlas Venture Life Science Advisors LLC significantly reduced its stake in Kymera Therapeutics, Inc. by 37.8% in the second quarter, selling 1.73 million shares. Despite this, Kymera remains Atlas Venture's largest holding, and analysts maintain a "Moderate Buy" rating with an average price target of $128.70. The company reported strong Q2 earnings, exceeding revenue and EPS estimates, although company insiders sold a substantial amount of stock during the quarter.
UBS Asset Management Americas LLC reduced its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 15.9% in the second quarter, selling 139,006 shares and retaining 736,866 shares valued at $84.5 million. This comes as Kymera Therapeutics reported a significant 465.2% year-over-year revenue increase to $65 million and beat EPS estimates, though company insiders sold a substantial amount of shares. Analyst sentiment remains largely positive with a "Moderate Buy" rating and an average price target of $128.70.
Braidwell LP increased its stake in Kymera Therapeutics (NASDAQ:KYMR) by 12% in the second quarter, acquiring 40,604 additional shares to reach a total of 378,163 shares valued at approximately $43.4 million. Analysts maintain a "Moderate Buy" rating for the stock with an average price target of $128.70, while the company reported better-than-expected quarterly earnings despite significant insider selling.
Jupiter Topco LLC recently acquired 21,058 shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) valued at approximately $2.4 million, reflecting increased institutional interest. Despite significant insider selling totaling $386.2 million over the past 90 days, analysts maintain a "Moderate Buy" rating with an average price target of $128.70, following a strong earnings report where Kymera beat EPS expectations and saw revenue surge by 465.2% year over year. The company's stock currently trades at $118.63, with a market capitalization of $9.86 billion.